Predictive biological factors for late survival in patients with HER2-positive breast cancer

The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors for late...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Young-Joon, Oh, Se Jeong, Bae, Soo Youn, Kim, Eun-Kyu, Lee, Young-Jin, Park, Eun Hwa, Jeong, Joon, Park, Heung Kyu, Suh, Young Jin, Kim, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328940/
https://www.ncbi.nlm.nih.gov/pubmed/37420033
http://dx.doi.org/10.1038/s41598-023-38200-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328940/
https://www.ncbi.nlm.nih.gov/pubmed/37420033
http://dx.doi.org/10.1038/s41598-023-38200-y

Ejemplares similares